The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 medicines defect notification for Ponlimsi (denosumab) 60mg injection after Teva UK Limited reported a critical labelling error on product cartons. The cartons incorrectly state “For application to the skin” when the osteoporosis medication is licensed for subcutaneous injection only.
Key takeaways
- Teva UK has reported incorrect carton labelling for Ponlimsi denosumab 60mg injections
- Cartons wrongly state “For application to the skin” instead of subcutaneous injection
- The product vial and pre-filled syringe labels remain correct
MHRA Drug Safety Alert Classifications
Class 4 represents lowest risk level for product defects
Source: MHRA Classification System, 2024 | Georgian Medical Journal News
Labelling Error Details and Patient Safety
According to the MHRA notification EL(26)A/27, the defect affects only the outer carton packaging of Ponlimsi denosumab 60mg solution for injection in pre-filled syringes. The vial labels and pre-filled syringe labels contain the correct administration instructions, indicating subcutaneous injection as the licensed route of administration.
Denosumab is a monoclonal antibody used primarily for treating osteoporosis and preventing skeletal-related events in cancer patients with bone metastases. The medication must be administered subcutaneously, typically in the upper arm, upper thigh, or abdomen, by trained healthcare professionals or patients who have received proper instruction.
Regulatory Response and Risk Assessment
The MHRA’s Class 4 classification indicates this represents the lowest level of risk in the UK’s medicines defect reporting system. Class 4 notifications typically involve minor labelling discrepancies that do not pose immediate safety concerns, particularly when the primary product labelling remains accurate.
Healthcare professionals administering Ponlimsi should rely on the vial and syringe labelling rather than the outer carton information. The prescribing guidance for denosumab remains unchanged, with subcutaneous injection every six months for osteoporosis treatment.
The outer carton incorrectly states “For application to the skin” while the product is licensed exclusively for subcutaneous injection use
— MHRA Drug Safety Alert EL(26)A/27 (2024)
Clinical Impact and Healthcare Provider Guidance
Teva UK Limited identified the labelling discrepancy through routine quality monitoring procedures and promptly reported the issue to the MHRA. The company has confirmed that no other components of the product packaging contain incorrect information, and the Summary of Product Characteristics (SmPC) accurately reflects the licensed indication.
Healthcare facilities should verify that staff are aware of the correct administration route for denosumab products and continue following established protocols for subcutaneous injection. Patients receiving home administration should be reminded of proper injection techniques during their next clinical review.
What this means
Frequently asked questions
Should patients stop taking their prescribed denosumab?
No, patients should continue their treatment as prescribed. The medication itself is unaffected, and only the outer carton labelling contains incorrect information.
How can healthcare providers identify affected batches?
The MHRA notification applies to Ponlimsi denosumab 60mg pre-filled syringes where the carton states “For application to the skin” instead of subcutaneous injection.
What should happen to incorrectly labelled stock?
Healthcare facilities should continue using the product while ensuring staff are aware of the correct subcutaneous administration route, as this is a Class 4 (lowest risk) defect.
The incident highlights the importance of multi-layered quality control systems in pharmaceutical manufacturing and the effectiveness of the UK’s medicines defect reporting framework. Healthcare providers should maintain awareness of product labelling discrepancies while ensuring patient treatment continuity for this essential bone health medication.
Source: Class 4 Medicines Defect Notification: Teva UK Ltd, Ponlimsi (Denosumab) 60mg Solution for Injection
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
